Coronavirus Vaccine / India's vaccine is giving hope to the whole world, know what the international organization said

Zoom News : Jul 09, 2021, 07:03 AM
New Delhi. India's indigenous vaccine Covaxin has been praised by the Chief Scientist of the World Health Organization on Thursday. Dr. Soumya Swaminathan has said that the trial data of the third phase of the vaccine are good. After the seal from the Chief Scientist, now the hopes of getting WHO approval for Covaccine have increased. In an article published on GAVI, the global organization for the availability of vaccines, Covaccine has been described as a promising vaccine.

In this article published on Gavi's website, Covaccine has been described as a vaccine with a high-efficiency rate. In addition, the article also clarifies that common symptoms such as fever and body pain emerge after vaccination with Covaccine. No serious side effects have been observed so far. Apart from India, Covaccine has got emergency use approval in 15 countries. These include countries like Zimbabwe, Iran, Mexico, Philippines, Guatemala and Botswana.

The article says that the vaccine is made in the traditional way. That is, in this the dead virus is inserted inside the body, due to which the body recognizes the virus and makes antibodies against it. This is called an inactivated whole virus vaccine.

Gavi is a public-private global health partnership to provide vaccines to low- and middle-income countries. It ensures that worldwide vaccine programs reach poor and middle-income countries in addition to rich countries.

In May, Bharat Biotech applied to the WHO for emergency use listing. It was said that the vaccine could be included in the list by July-September. There was a pre-submission meeting between WHO and Bharat Biotech on 23 June. Once Bharat Biotech submits complete data for the Phase-3 trial of the vaccine, the dossier will be completed and the organization will review it. The company expects the EUL application review process to begin in July after the submission of the Efficacy Study data.

SUBSCRIBE TO OUR NEWSLETTER